Author: [AUTHOR] Published on 5/15/2024 4:00:00 PM
FDA Office of Clinical Pharmacology Seeks Public Input on Opportunities and Priorities
The US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Translational Sciences (OTS) announces the availability of the 2023 OTS Annual Report.
OTS contributes to CDER’s mission by performing drug regulatory reviews, actively engaging in regulatory science research, and facilitating CDER research activities to drive innovation and advances in the science of drug development. The office helps establish technology transfer agreements, supports CDER’s intramural and extramural research programs, and promotes collaborations between CDER scientists and its external stakeholders on topics that advance regulatory decision-making and encourage innovation in the development, manufacture, and safe use of drugs.
- Drug development and regulatory review
- Substance use disorders
- Inspections
- Science and research
- Advancing tools, technologies, and innovation
- Outreach and communications efforts
- To learn more about how OTS supports advances in human health through scientific and regulatory innovation, please visit the 2023 OTS Annual Report.
The Office of Clinical Pharmacology (OCP) is pleased to offer the e-mail subscription service Clinical Pharmacology Corner. This is a free service from FDA to provide occasional updates from OCP regarding newly approved therapies, new regulatory and scholarly publications, upcoming events and other items of interest. Subscribe today or click the button below select Clinical Pharmacology Corner under Drugs.
We always welcome your thoughts regarding the format, content, and utility of this communication. Comments may be sent via email to ocp@fda.hhs.gov.
This communication was prepared by Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.
Subscribe Now
